Kiadis Pharma receives regulatory approval for next trials for ATIR101 and ATIR201
Kiadis Pharma N.V. , a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for...
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute...
Selvita , a clinical stage drug discovery and development company focused on innovative medicines for...
LEO Pharma announces positive results from phase 2b clinical study for tralokinumab in atopic...
LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study...
Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging...
Inovio Pharmaceuticals, Inc. announced that Dr. David B. Weiner, Inovio’s co-founder, presented positive clinical data...
Delmar Pharmaceuticals announces dosing of first patient in Phase two clinical trial of VAL-083
DelMar Pharmaceuticals, Inc , a biopharmaceutical company focused on the development and commercialization of new...
Aslan pharmaceuticals announces first patient enrolled in phase 1 study of Varlitinib in japan
ASLAN Pharmaceuticals , a biotech company focused on the development of immunotherapies and targeted agents...
Envisia therapeutics releases interim Env515 phase 2 data results
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in...
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial
Astellas Pharma Inc and Ironwood Pharmaceuticals Inc announced top-line results indicating that the Phase III...
New UK primary care clinical trials company Interface Clinical Research to offer a more...
New clinical trials company, Interface Clinical Research, outlined a new model for running primary care...
Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
Pluristem Therapeutics Inc , a leading developer of placenta-based cell therapy products, today announced that it...
